SALT LAKE CITY, Feb. 13, 2014 (GLOBE NEWSWIRE) -- Amedica Corporation (Nasdaq:AMDA) today announced the pricing of its initial public offering of 3,500,000 shares of common stock at a public offering price of $5.75 per share. In addition, Amedica has granted the underwriters a 30-day option to purchase up to an additional 525,000 shares of common stock from Amedica at the public offering price, less underwriting discounts. The offering is expected to close on February 19, 2014, subject to customary closing conditions. Amedica's common stock has been approved for listing on the NASDAQ Capital Market and is expected to begin trading under the ticker symbol "AMDA" on February 13, 2014.
JMP Securities LLC is acting as the sole book-running manager for the offering. Needham & Company, LLC is acting as co-manager for the offering.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on February 12, 2014. The offering will be made only by means of a prospectus. A copy of the final prospectus relating to these securities will be filed with the SEC and may be obtained, when available, from JMP Securities LLC by mail at JMP Securities LLC, Attention: Syndicate Department, 600 Montgomery Street, Suite 1100, San Francisco, CA 94111, by email firstname.lastname@example.org, or by phone at (415) 835-8900, or from Needham & Company, LLC by mail at Needham & Company, LLC, 445 Park Avenue, 3rd Floor, New York, NY 10022, by email email@example.com, or by phone at (800) 903-3268.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Amedica Corporation
Amedica is a commercial biomaterial company focused on using its silicon nitride technology platform to develop, manufacture and sell a broad range of medical devices. Amedica markets spinal fusion products and is developing product candidates for use in total hip and knee joint replacements. Amedica operates an ISO 13485 certified manufacturing facility and its spine products are FDA cleared, CE marked, and are currently marketed in the U.S. and in select markets in Europe and South America. Amedica is based in Salt Lake City, Utah.
CONTACT: Amedica CorporationBill Hockett, Investor Relations